These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28772290)

  • 1. Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging.
    Ballinger ML; Ferris NJ; Moodie K; Mitchell G; Shanley S; James PA; Thomas DM
    JAMA Oncol; 2017 Dec; 3(12):1735-1736. PubMed ID: 28772290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
    Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
    Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
    Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
    Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance of Dutch Patients With Li-Fraumeni Syndrome: The LiFe-Guard Study.
    Ruijs MWG; Loo CE; van Buchem CAJM; Bleiker EMA; Sonke GS
    JAMA Oncol; 2017 Dec; 3(12):1733-1734. PubMed ID: 28772294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic
    Bancroft EK; Saya S; Brown E; Thomas S; Taylor N; Rothwell J; Pope J; Chamberlain A; Page E; Benafif S; Hanson H; Dias A; Mikropoulos C; Izatt L; Side L; Walker L; Donaldson A; Cook JA; Barwell J; Wiles V; Limb L; Eccles DM; Leach MO; Shanley S; Gilbert FJ; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA; Walker LG
    J Med Genet; 2020 Apr; 57(4):226-236. PubMed ID: 31719169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial.
    Caron O; Frebourg T; Benusiglio PR; Foulon S; Brugières L
    JAMA Oncol; 2017 Dec; 3(12):1736-1737. PubMed ID: 28772306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
    Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
    Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.
    Ballinger ML; Best A; Mai PL; Khincha PP; Loud JT; Peters JA; Achatz MI; Chojniak R; Balieiro da Costa A; Santiago KM; Garber J; O'Neill AF; Eeles RA; Evans DG; Bleiker E; Sonke GS; Ruijs M; Loo C; Schiffman J; Naumer A; Kohlmann W; Strong LC; Bojadzieva J; Malkin D; Rednam SP; Stoffel EM; Koeppe E; Weitzel JN; Slavin TP; Nehoray B; Robson M; Walsh M; Manelli L; Villani A; Thomas DM; Savage SA
    JAMA Oncol; 2017 Dec; 3(12):1634-1639. PubMed ID: 28772291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased sperm aneuploidy in two male carriers of germline TP53 mutations.
    Paulasova P; Diblik J; Trkova M; Macek M; Sedlacek Z
    Cancer Genet; 2011 May; 204(5):278-81. PubMed ID: 21665182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surveillance recommendations for patients with germline TP53 mutations.
    Ballinger ML; Mitchell G; Thomas DM
    Curr Opin Oncol; 2015 Jul; 27(4):332-7. PubMed ID: 26049273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmission of a
    Cotter JA; Szymanski L; Karimov C; Boghossian L; Margol A; Dhall G; Tamrazi B; Varaprasathan GI; Parham DM; Judkins AR; Biegel JA
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29581140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
    Omran M; Johansson H; Lundgren C; Silander G; Stenmark-Askmalm M; Loman N; Baan A; Adra J; Kuchinskaya E; Blomqvist L; Tham E; Bajalica-Lagercrantz S; Brandberg Y;
    Cancer; 2023 Mar; 129(6):946-955. PubMed ID: 36601958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations.
    Kasper E; Angot E; Colasse E; Nicol L; Sabourin JC; Adriouch S; Lacoume Y; Charbonnier C; Raad S; Frebourg T; Flaman JM; Bougeard G
    Eur J Cancer; 2018 Sep; 101():254-262. PubMed ID: 30072235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline TP53 mutations and Li-Fraumeni syndrome.
    Varley JM
    Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel TP53 germline mutation in a large Italian Li-Fraumeni syndrome Family.
    Capra V; Consales A; Nozza P; Monti P; Inga A; Fronza G
    Pediatr Blood Cancer; 2009 Feb; 52(2):303-4. PubMed ID: 18937320
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
    Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA
    JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and Management of
    Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
    South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex-specific effect of the TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers.
    Fang S; Krahe R; Bachinski LL; Zhang B; Amos CI; Strong LC
    Hum Genet; 2011 Dec; 130(6):789-94. PubMed ID: 21688173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parent decision-making around the genetic testing of children for germline TP53 mutations.
    Alderfer MA; Zelley K; Lindell RB; Novokmet A; Mai PL; Garber JE; Nathan D; Scollon S; Chun NM; Patenaude AF; Ford JM; Plon SE; Schiffman JD; Diller LR; Savage SA; Malkin D; Ford CA; Nichols KE
    Cancer; 2015 Jan; 121(2):286-93. PubMed ID: 25223899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.